ANeuroTech To Launch Pivotal Program With New Dose Of Old Antidepressant
Pipamperone Promise In MDD
The Belgian firm has the go-ahead from the US FDA for an advanced depression program for ANT-01 including the endpoint of improvement in cognitive function, which could differentiate its label.
You may also be interested in...
Since its emergence in the spring, the monkeypox outbreak has spawned a small but growing pipeline of drugs and vaccines, many of them repurposed smallpox products.
After highlighting oncology drugs pegged to make a splash next year with the help of Biomedtracker, Scrip takes a look at seven potential blockbusters across a range of therapeutic areas including neurology, dermatology and blood disorders slated for approval next year.
Nirsevimab is set to become the second RSV prophylactic on the market for infants and offers several advantages over its first-to-market competition, but Pfizer’s vaccine rival is fast approaching.